ForteBio is now part of the Sartorius group. Click here for more

Pioneer and Pioneer FE Systems

Complete solution for biomolecular interaction analysis with next generation SPR injections

Next generation OneStep® SPR injections enables users to identify hits faster, obtain more information-rich data, and eliminate sample dilutions

Pioneer SPR systems provide high quality kinetic data (ka, kd) and affinity measurements (KD) to chracterize a wide range of biomolecular interactions from small molecule fragments to biologics. OneStep SPR injections enable faster assay workflows where a single analyte concetration is sufficient for accurate kinetics and affinity determination.

meOneStep SPR Systems
  •  

    Simplified kinetic chracterizations

    With OneStep injections, users can obtain accurate kinetic and affinity values from one analyte concentration eliminating the need to run multiple analyte titrations saving time and error associated with making dilutions. NextStep injections provide a simple workflow to characterize competitive binders against a ligand to capture the mechanism of action.

  •  

    Robust fluidics design

    Pioneer fluidic system is made up of inert materials such as PEEK, ceramic and Tefzal providing durability and low maintenance.

  •  

    Low baseline noise, minimal drift, high sensitivity and up to 40 Hz data collection rate

    Extremely low baseline noise and drift enable measurement of reliable kinetics and affinity values for high affinity and challenging binders. With up to 40 Hz of data acquisition capabilities, Pioneer FE systems are capable of capturing very fast kinetic association and dissociation phases of a wide range of biomolecules and small molecule fragments.

  • 3 channel, fully automated SPR system

    With three sensing channels, two target proteins or ligands can be analyzed simultaneously for binding with one surface utilized as a reference channel.

  • Screen 768 fragments in 24 hours

    Pioneer FE platform's high-throughput screening feature enables kinetic screening of 768 small molecule fragments in a single experiment in 24 hours.

  • Up to 72 hours of unattended run time

    Offers a variety of sample vessel formats with up to two 384 well plate capacity with an unattended runtime of about 72 hrs for performing large binding screens.

  • Rapid data analysis with QDat software and hit selection feature

    Pioneer SPR systems are equipped with an integrated, industry-proven data analysis software based on Scrubber and Clamp platforms. Raw data across multiple runs, days, and sensors can be combined and analyzed using binding algorithms such as single site, multi-site binding, mass transport, and irreversible inhibitor analysis as required for analysis. Hit-selection software feature enables rapid identificatoin of frgment hits that are acquired by Pioneer FE SPR systems.

  • Gain more data with less

    As the analyte gradient is generated in OneStep injections, the diffusion coefficient is calculated that provides an assessment of aggregation enabling users to gain information not only on kinetics and affinity but also on aggregation in just one injection. 

Characterization of high affinity biologic interactions

Target binding characterization is an essential analytical step for the selection of high affinity (KD <1 nM) and highly specific biologics regardless of the types of molecules. A kinetic analysis further describes the components of association and dissociation that comprise the overall affinity interaction. For example, two lead compounds may possess a similar affinity (KD) to its target, but their differences in kinetic rate constants of association and dissociation can be used to estimate which will be more useful in vivo. Accurate analysis of these kinetic rate constants is therefore important information for lead selection and predicting the efficacy of protein therapeutics. The Pioneer SPR system with next generation SPR injections improves the efficiency of the characterization process over traditional SPR by determining the kinetics and affinity in a single step. The next-generation OneStep® gradient injection featured on the Pioneer platform dramatically increases the speed of affinity characterization while maintaining accuracy and high confidence in results.

Characterize irreversible inhibitors and measure commitment to covalency

The majority of small molecule inhibitor assays tested with label-free, real-time biosensor technologies are reversible interactions, characterized by commonly used kinetic rate models. However, a significant fraction of therapeutic enzyme inhibitors on the market functions through covalent modification of the target. ForteBio's Pioneer FE is a SPR platform that can be used with regenerable Streptavidin biosensors to reversibly capture protein targets and quantify the efficiency of covalent inhibitors binding to the target. The Pioneer FE system's irreversible inhibitor applications method can be used to determine inhibitor compound's commitment to covalency (Cc) as a metric for irreversible inhibitors.

Fragment screening

Fragment-based drug design has become an increasingly popular platform for the identification of lead candidates in drug discovery programs. The detection and characterization of fragment binding events is facilitated by sensitive biophysical technologies capable of detecting low affinity interactions of low molecular weight compounds. Surface plasmon resonance (SPR) has become one of the core technologies used in the identification of these low-affinity fragment compounds. SPR-based biosensors such as the Pioneer FE have the necessary sensitivity and throughput to provide complete fragment screens on libraries of several thousand compounds in just a few weeks per target.

 

Pioneer FE SPR System

Pioneer SPR System

Refractive Index Range

1.33–1.40

1.33–1.40

Short Term Noise

< 0.035 RU

< 0.1 RU

Molecular Weight Cutoff

< 70 Da

< 70 Da

Working Ranges

ka 102 – 109 M-1 s-1
kd 10-6 – 2.5 s-1
KD ~10-3 – 10-12 M
Concentration ~10-3 – 10-12 M

ka 102 – 108 M-1 s-1
kd 10-6 – 0.1 s-1

Sample Capacity

2 sample racks

2 sample racks

Sample Configuration

96 vial, deep well and PCR formats, 384-well microplates, custom high volume

96 vial, deep well and PCR formats, 384 well microplates, custom high volume

Sample Temperature Control

4 to 40°C (max 15° below ambient)

4 to 40°C (max 15° below ambient)

Sample loading

Automatic

Automatic

Number of Channels

3

3

Flow Channel Volume

1, 1–2, 1–2–3, 3, 3–2, 3–2–1

1, 1–2, 1–2–3, 3, 3–2, 3–2–1

Reference Curve Subtraction

Yes

Yes

Injection Volume

2–700 μL

2–700 μL

Simultaneous Injections

Yes, dual sample loops

Yes, dual sample loops

Inline Buffer Degassing

Yes

Yes

System Temperature Control

4–40°C (Max 15° below ambient)

4–40°C (Max 15° below ambient)

Variable Data Rate

1–40 Hz

1–20 Hz

Automation Capabilities

> 72 hour unattended operation

> 72 hour unattended operation

Qdat hit selection feature

Yes

No

High-throughput screening mode

Yes

No

Resources of Pioneer and Pioneer FE Systems

Application Note Commitment to Covalency : Kinetics of Irreversible Inhibitors on the Pioneer FE System

The principal role of assay groups in drug discovery is to provide reliable methods, analysis, and data for confident decision-making about series progression. Particular assays are chosen to differentiate between affinity, specificity, cellular action, and most important mechanism of action.

Read more

Application Note Fragment Based Drug Discovery on Pioneer Systems Using Next Generation SPR Analysis

Fragment-based drug design (FBDD) has become an increasingly popular platform for the identification of lead candidates in drug discovery programs. The detection and characterization of fragment binding events is facilitated by sensitive biophysical technologies capable of detecting low-affinity interactions of low molecular weight compounds. Over the last decade approaches such as nuclear magnetic resonance (NMR), X-ray crystallography, differential scanning fluorimetry (DSF), and surface plasmon resonance (SPR) have become core technologies in many pharma

Read more

Application Note OneStep Lead Characterization of High Affinity Biologic Interactions with Pioneer SPR Systems

Biopharmaceutical drug discovery and development have celebrated the approval of breakthrough treatments in diseases of inflammation, cancer and infectious disease in recent years. As the biopharma industry sees more therapeutic successes, the problems left to solve in medicine will prove increasingly more difficult.

Read more

eBook Label-free detection: technologies, key considerations, and applications

Interactions between biomolecules serve as key triggers for many biological processes and, therefore, provide perfect targets for drug discoveries.

Read more

Brochure Pioneer and Pioneer FE Systems

Pioneer and Pioneer FE systems provide high quality kinetics (ka , kd ) and affinity (KD) measurements in a single injection in a matter of minutes. They use surface plasmon resonance (SPR) technology to rapidly characterize a wide variety of biomolecular interactions from small molecule fragments to biologics, without compromising sensitivity. Pioneer systems provide rapid affinity data (KD) directly from primary screens, significantly reducing the time and cost associated with secondary screening while enabling the prompt identification of lead candidates.

Read more

Flyer OneStep Injection technology – SPR-based screening and characterization

OneStep provides the information content equivalent to the first three steps in a traditional SPR fragment screen using a single injection per fragment.

Read more

Flyer SPR biosensor selection guide – Pioneer Systems

Read this document which is helpful in the selection of SPR Biosensor with their detail information.

Read more

Flyer The next generation of SPR-based interaction analysis

Pioneer SPR systems from ForteBio employ a novel gradient injection technology that combines the accuracy and sensitivity of traditional SPR analysis with the benefits of simpler assay set-up, shorter run times, reduced sample consumption, and higher throughput.

Read more

Scientific Poster Surface Plasmon Resonance: SensiQ Pioneer as a means to screen drug discovery fragments for hits

Common approaches to the identification of hits from small molecules or fragments are via high-throughput screening (HTS) assays and/or surface plasmon resonance (SPR). The aims of this study were to validate the hits from a high-throughput (HT) SPR assay with a well-characterised HTS enzymatic assay against an undisclosed target.

Read more

We use cookies to personalize content and improve your browsing experience.

We also use analytics & advertising services. To opt-out click for more information.